Product information and disease descriptionPlace of product in therapyApproaches to treatment
Place in treatment, anticipated use, and care setting
1 evidence topic · 4 sources
Summary
The proposed post-platinum use includes participants previously treated with or without amivantamab. REZILIENT1 evaluates oral monotherapy, whereas REZILIENT3 evaluates first-line Zipalertinib with platinum-pemetrexed chemotherapy. These regimens and populations should be considered separately. Pre-approval access requests must come from physicians and do not guarantee access.